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*Appendix 1.
Identifying genetic risk factors underpinning different aspects of Alzheimer’s disease has the potential to provide important insights
into pathogenesis. Moving away from simple case-control deﬁnitions, there is considerable interest in using quantitative endophe-
notypes, such as those derived from imaging as outcome measures. Previous genome-wide association studies of imaging-derived
biomarkers in sporadic late-onset Alzheimer’s disease focused only on phenotypes derived from single imaging modalities. In
contrast, we computed a novel multi-modal neuroimaging phenotype comprising cortical amyloid burden and bilateral hippocam-
pal volume. Both imaging biomarkers were used as input to a disease progression modelling algorithm, which estimates the
biomarkers’ long-term evolution curves from population-based longitudinal data. Among other parameters, the algorithm com-
putes the shift in time required to optimally align a subjects’ biomarker trajectories with these population curves. This time shift
serves as a disease progression score and it was used as a quantitative trait in a discovery genome-wide association study with
n = 944 subjects from the Alzheimer’s Disease Neuroimaging Initiative database diagnosed as Alzheimer’s disease, mild cognitive
impairment or healthy at the time of imaging. We identiﬁed a genome-wide signiﬁcant locus implicating LCORL (rs6850306,
chromosome 4; P = 1.03  108). The top variant rs6850306 was found to act as an expression quantitative trait locus for
LCORL in brain tissue. The clinical role of rs6850306 in conversion from healthy ageing to mild cognitive impairment or
Alzheimer’s disease was further validated in an independent cohort comprising healthy, older subjects from the National
Alzheimer’s Coordinating Center database. Speciﬁcally, possession of a minor allele at rs6850306 was protective against conver-
sion from mild cognitive impairment to Alzheimer’s disease in the National Alzheimer’s Coordinating Center cohort (hazard
ratio = 0.593, 95% conﬁdence interval = 0.387–0.907, n = 911, PBonf = 0.032), in keeping with the negative direction of effect
reported in the genome-wide association study (bdisease progression score = 0.07  0.01). The implicated locus is linked to genes
with known connections to Alzheimer’s disease pathophysiology and other neurodegenerative diseases. Using multimodal imaging
phenotypes in association studies may assist in unveiling the genetic drivers of the onset and progression of complex diseases.
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Introduction
Alzheimer’s disease is the most common cause of dementia,
affecting 46.8 million people worldwide (Prince et al.,
2015). The pathophysiology of Alzheimer’s disease and
its genetic drivers have been widely studied in recent
years. The "4 allele of the apolipoprotein E gene
(APOE4) is the strongest known common genetic risk
factor for sporadic late-onset Alzheimer’s disease
(Saunders et al., 1993). Further genetic risk factors have
been identiﬁed through genome-wide association studies
(GWAS) in case-control datasets, with recent studies com-
prising 74 000 subjects (Lambert et al., 2013). However,
case-control studies in a disorder where the prodromal
stage spans decades neglect the fact that many participants
labelled as controls may be future cases and therefore
reduces statistical power of the study.
An increasingly popular alternative to genetic studies in
case-control settings is the genome-wide screen for effects
on quantitative disease biomarkers. These biomarkers,
often referred to as endophenotypes, are believed to
better reﬂect the underlying disease processes and also
enable studies investigating the genetic inﬂuences on disease
development in the prodromal phase. In the context of
Alzheimer’s disease, various quantitative traits have been
investigated. A considerable proportion of these studies
focused on biomarkers derived from brain image analysis,
such as grey matter density in several structures from MRI
(Potkin et al., 2009; Shen et al., 2010), voxel-wise measures
of brain atrophy (Stein et al., 2010), and cross-sectional
and longitudinal amyloid burden from PET (Ramanan
et al., 2014, 2015). Other studies have investigated
plasma- or CSF-based biomarkers, which include levels of
amyloid-b1-42, total and phosphorylated tau, and apolipo-
protein J (Cruchaga et al., 2013; Deming et al., 2016;
Piccio et al., 2016). These efforts have led to the identiﬁ-
cation of additional genetic risk factors, such as IL1RAP
(Ramanan et al., 2015), which remained concealed even in
large genome-wide case-controls studies.
Complex diseases, such as Alzheimer’s disease, are asso-
ciated with sequences of changes in multiple disease-speciﬁc
biomarkers. However, disease progression from the preclinical
to advanced stage can take decades, and different biomarkers,
reﬂecting different pathologies may show dynamic changes at
speciﬁc disease stages (Jack et al., 2010, 2013). Thus, testing
each biomarker independently in genetic studies provides in-
sights into one speciﬁc disease-related process (i.e. atrophy,
amyloid deposition, neuroﬁbrillary tangles formation) in a
limited time window. Recent methodological developments
enable the estimation of data-driven models of disease pro-
gression involving multiple biomarkers (Donohue et al., 2014)
and therefore provide more robust disease staging of patients.
The approach by Donohue et al. (2014) models continuous
long-term biomarker evolution from short-term longitudinal
data. In contrast, the discrete event-based model by Fonteijn
et al. (2012) focuses on the order in which biomarkers
become abnormal. Both approaches provide an integrated
view on the wide range of biomarker changes and aim to
accurately stage patients and to predict future disease
progression. For this reason, we introduce the disease progres-
sion score (DPS) as a quantitative phenotype for genetic
association studies. DPS provides an integrated view on
pathophysiological changes during disease development and
potentially provides novel genetic insights, which are different
from the ones gained by studying single biomarkers. DPS
effectively collapses multiple sources of information and
multiple time points into a single metric, and is therefore
multi-modal by design. The rationale behind DPS as pheno-
types is 2-fold: DPS enables multi-phenotype analyses, and
also incorporates multiple time points for each biomarker,
so as to have an holistic perspective of the patient’s disease
history. This is something that existing multivariate analysis
tools, such as MV-Plink (Ferreira and Purcell, 2009),
SNPTEST (Marchini et al., 2007), BIMBAM (Servin and
Stephens, 2007) or MultiPhen (O’Reilly et al., 2012), are un-
able to achieve, because they only allow for the combination
of P-values from the testing of multiple biomarkers at the
same time point in a cross-sectional setting.
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In this work we present the ﬁrst GWAS of an Alzheimer’s
disease DPS derived from two imaging modalities
[T1-weighted MRI and amyloid PET (
18F-ﬂorbetapir)] on
a large cohort from the ADNI database (Jack et al.,
2008). We investigated the DPS properties as an endophe-
notype and compared GWAS results to single-modality
cross-sectional biomarkers. We also compared association
strengths to genome-wide polygenic risk scores across
phenotypes. Lastly, we investigated our GWAS results in
the National Alzheimer’s Coordinating Center (NACC)
database, to assess their effect on the risk of conversion
from healthy ageing to mild cognitive impairment (MCI)
or Alzheimer’s disease.
Materials and methods
Data used in the preparation of this article were obtained from
the ADNI database (http://adni.loni.usc.edu). The ADNI was
launched in 2003 as a public-private partnership, led by
Principal Investigator Michael W. Weiner, MD. The primary
goal of the ADNI has been to test whether serial MRI, PET,
other biological markers, and clinical and neuropsychological
assessment can be combined to measure the progression of
MCI and early Alzheimer’s disease. For up-to-date information,
see www.adni-info.org.
Diagnosis
Diagnosis at the time of the ﬁrst ﬂorbetapir PET scan was used
in subsequent analyses. Diagnostic categories were healthy con-
trol, subjective memory complaints, early MCI/late MCI and
Alzheimer’s disease. For the association analysis with polygenic
risk scores (see ‘SNP effect on risk of conversion’ section),
the latest diagnosis available in ADNI was used (healthy con-
trol/MCI/Alzheimer’s disease, date accessed 05/11/2015).
Furthermore, diagnosis at baseline ﬂorbetapir PET scan and
latest diagnosis were compared to deﬁne clinical progression
(i.e. stable, conversion or reversion) for each subject.
Genotyping and imputation
At the time of this study single nucleotide polymorphism (SNP)
genotyping data were available for 1674 subjects across all
ADNI phases. Genotyping was conducted using three different
platforms: Human610-Quad, HumanOmniExpress and Omni
2.5M (Illumina) (Saykin et al., 2010). The proportions of
study participants genotyped with each platform and their
relationship with diagnosis at baseline can be found in
Supplementary Table 1.
Autosome imputation and quality control
Following recommendations by Roshyara et al. (2014),
pre-imputation autosomal SNP ﬁltering based on call rate was
omitted. On the subject level we performed the following qual-
ity control steps: (i) sex checks were conducted on the original
genotype ﬁles separately by platform and reported no mis-
matches; (ii) we computed subject-level call rate on the original
genotype ﬁles separately by platform and reported no subject
missing more than 10% genotypes; (iii) relatedness analysis was
performed on genotyped SNPs before imputation: the Genetic
Relationship Matrix (GRM) was computed in PLINK v1.9
(Chang et al., 2015) and pruned at 0.1, a threshold lower
than the coefﬁcient of relatedness for ﬁrst cousins (via the –
rel-cutoff 0.1 command). On the SNP level we conducted
basic checks to ensure compatibility with the reference panel
used for imputation. Speciﬁcally, we used a tool by W.
Rayner (http://www.well.ox.ac.uk/wrayner/tools/), to check
SNPs for strand consistency, allele names, position, Ref/Alt as-
signments and minor allele frequency (MAF) differences with
the reference panel. The Sanger Imputation Server (https://im-
putation.sanger.ac.uk/) was used with SHAPEIT for phasing
(Delaneau et al., 2011), Positional Burrows-Wheeler
Transform (Durbin, 2014) for imputation and the Haplotype
Reference Consortium version 1.1 (McCarthy et al., 2016) as
reference panel. Data from the three different genotyping plat-
forms were imputed separately. Quality control was performed
on genotyped and imputed SNP calls with PLINK. Multi-allelic
variants and SNPs with imputation INFO score 5 0.3 were
removed. Following the initial quality control, genotypes from
the three platforms were merged. Genotype calls with posterior
probability 5 0.9 were set to missing. Next, SNPs with MAF
5 5%, genotyping rate 5 90%, or deviation from Hardy-
Weinberg equilibrium (P5 5.7  107) were excluded.
Finally, subjects missing 10% or more of the genotypes were
removed.
SNPweights (Chen et al., 2013) was used to infer genetic an-
cestry from genotyped SNPs. Ancestry adjustment in the ADNI
cohort was implemented in two steps: (i) subjects were compared
against a reference panel comprising Central European, Yoruba
Africans and East Asian from HapMap 3 (Altshuler et al.,
2010), and native Americans from Reich et al. (2012). Subjects
with 4 80% of Central European genetic ancestry were kept
(157 subjects removed); (ii) SNPweights was used together with
a reference panel from the Framingham Heart Study (Dawber
et al., 1951) comprising north-western Europeans, south-eastern
Europeans and Ashkenazi Jewish in order to compute two prin-
cipal components of population structure to be used in the fol-
lowing association tests (Supplementary Fig. 1).
X chromosome variants
Variants on the X chromosome underwent recommended pre-
imputation quality control provided with the X-wide analysis
toolset (XWAS version 1.1) (Gao et al., 2015) using the follow-
ing parameters: exclusion of genotype calls with MAF 5 5%,
missingness rate 4 10%, deviation from Hardy-Weinberg equi-
librium with P5 0.05 (Bonferroni corrected); exclusion of sam-
ples with 410% missing genotypes and high relatedness (GRM
off-diagonal relatedness coefﬁcient 4 0.1). At the time of manu-
script preparation, the Sanger server did not support imputation
of X chromosome variants. Thus, we applied an in-house imput-
ation pipeline for this task, using the 1000 Genomes Project data
as a reference panel (Durbin et al., 2010), SHAPEIT (Delaneau
et al., 2011) for phasing and IMPUTE2 for imputation
(Marchini and Howie, 2010). Pseudo-autosomal regions were
excluded, and the 1000 Genomes Project panel without
pseudo-autosomal regions was used for imputation. Post-imput-
ation quality control was performed with XWAS applying the
following exclusion criteria: imputation INFO score 5 0.3;
MAF 5 5%; genotyping (or imputation) rate 5 90% per geno-
type; deviation from Hardy-Weinberg equilibrium with P50.05
(Bonferroni corrected).
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Image processing
Cortical amyloid burden
At the time of this study, 2034 preprocessed longitudinal
18F-ﬂorbetapir PET scans for 1089 subjects were available in
the ADNI database (date accessed 24/03/2016). Preprocessing
of ﬂorbetapir PET scans in ADNI has been described in detail
elsewhere (Jagust et al., 2010). Brieﬂy, four 5-min frames
were acquired 30–60min post-injection; dynamic frames were
co-registered to the base frame image, averaged, reoriented into
a standard space (voxel grid size 160  160  96, voxel size
1.5  1.5  1.5mm3), and smoothed down to the lowest reso-
lution available in ADNI (8mm full-width at half-maximum uni-
form isotropic).
To compute the standardized uptake value ratio (SUVR),
information from structural magnetic resonance scans was
used. A total of 1931 preprocessed T1-weighted magnetic
resonance scans (voxel size 1  1  1.2mm3) were down-
loaded for the same subjects. Details about the magnetic res-
onance preprocessing can be found in Jack et al. (2008). Each
ﬂorbetapir PET scan was time-matched to the closest-in-time
magnetic resonance scan. However, because of missing concur-
rent MRI scans for 100 individuals, one or more ﬂorbetapir
PET scans were time-matched to the same magnetic resonance
scan. Figure 1 depicts a schematic of the implemented image
processing pipeline. The GIF algorithm (Cardoso et al., 2015)
and the Aladin algorithm implemented in NiftyReg (Ourselin
et al., 2001) were used for segmentation and registration, re-
spectively. PET-T1 registrations were visually assessed to
ensure correct alignment.
SUVRs were computed as a measurement of cortical amyloid
deposition for each subject and time point. The SUVs were
computed as the weighted sum of the ﬂorbetapir PET signal
intensities with weights corresponding to voxel-wise cerebral
Figure 1 Image processing pipeline for the amyloid load computation. GIF was used to obtain a probabilistic segmentation of the
T1-weighted scans into background/skull, grey matter, white matter, CSF, subcortical structures, brainstem/pons and cerebellar nuclei. Each
T1-weighted scan was rigidly registered to the closest-in-time florbetapir PET scan using the Aladin algorithm; a cubic spline interpolation scheme
in two steps was used to resample the warped T1 image to the space of the closest-in-time lower-resolution PET. The GIF segmentations were
resampled to the space of the PET scan, to define two key regions: (i) a cortical target region excluding the cerebellar grey matter; and
(ii) a composite reference region comprising white matter, whole cerebellum, brainstem and pons, as proposed by Landau et al. (2015).
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grey matter probability. The SUVR is then deﬁned as the SUV
in the cortical region divided by the SUV in the reference
region. The probability-weighted sum to compute SUVs con-
trols for partial volume effects. A composite reference region
comprising white matter, whole cerebellum, brainstem and
pons was used (Landau et al., 2015). The SUVR cut-off used
to determine amyloid status was obtained by transforming the
value of 0.79, as recommended by Landau et al. (2015) by
linear regression, yielding a value of 0.7585.
Hippocampal volume
Hippocampal volume longitudinal measurements for ADNI
was performed by N. Schuff and colleagues at UCSF using
FreeSurfer version 4.3 (Fischl et al., 2002) and accessed
through the ADNI website (date accessed 05/11/2015).
Hippocampal volumes were normalized by dividing by total
intracranial volume.
Disease progression modelling
The GRACE algorithm (Donohue et al., 2014) was used for
modelling disease progression curves from short-term longitu-
dinal individual trajectories of imaging biomarkers. Brieﬂy,
GRACE is based on self-modelling regression, which assumes
that the curves to be ﬁtted share a common shape, e.g. a sig-
moid in Alzheimer’s disease (Jack et al., 2013). GRACE itera-
tively applies regression splines to ﬁt the following model:
Yij tð Þ ¼ gj t þ  i
 þ 0ij þ 1ijt þ "ij tð Þ: ð1Þ
where Yij(t) is the value of biomarker j for subject i at time
t, gj is assumed to be a monotone function, 0ij and 1ij are a
random intercept and slope, respectively, allowed for each
subject, "ij(t) is the ﬁtting residual, and i is an unknown
subject-speciﬁc parameter. For each subject  i is estimated as
the shift in time required to optimally align the subjects’ bio-
marker trajectories with the estimated population long-term
progression curves. Once all subjects have been aligned, the
population curves are re-estimated and a new set of  i is
computed with respect to the updated population curves.
This process is iterated until convergence. We utilise the
ﬁnal  i parameters as a continuous DPS. The DPS provides
an estimate, based on the observed biomarker values, of how
advanced in the disease process a subject is compared to the
average of the cohort. The curves are all centred at t = 0, thus,
individuals with negative time shift, i.e. residing on the left
plateau of the sigmoid, are likely to be labelled as controls.
Conversely, highly abnormal values for the biomarkers place
a patient further in time on the standardized population tra-
jectory, approaching the right plateau of the sigmoid
(Supplementary Fig. 2). The DPS is computed by jointly con-
sidering the progression curves for all biomarkers. Thus, it
natively incorporates information derived from different ima-
ging modalities and renders it effectively as a multi-modal
imaging-derived phenotype.
Florbetapir SUVR and hippocampal volumes were used as
input for GRACE, after being Z-normalized with respect to





where Yij is the value of the j-th biomarker for the i-th subject,
and j and j are the mean and standard deviation of the j-th
biomarker among the healthy controls (see above), respect-
ively. This Z-score-based measure ranks the different bio-
markers according to disease severity with respect to healthy
controls. The independent variable for the ﬁtting procedure
was time from study entry (in years) because, from a compu-
tational perspective, GRACE implementation requires the
input independent variable to start from t = 0.
Statistical analysis
Phenotypic effect sizes for clinical diagnosis
Effect sizes for differentiating diagnostic categories of the
single-modality biomarkers (both cross-sectional baseline
values and longitudinal rates of change) and the DPS were
computed as Cohen’s d and 95% conﬁdence intervals (CI),
for three comparisons (healthy control versus Alzheimer’s dis-
ease, healthy control versus MCI, MCI versus Alzheimer’s
disease).
Disease progression score distributions
A one-way ANOVA and a Tukey’s range test were performed
to quantitatively assess pairwise differences in the DPS distri-
butions among the diagnostic groups at ﬁrst PET scan and the
clinical progression of healthy control and MCI subjects.
Relation between disease progression score and
Alzheimer’s disease genetic risk score
We hypothesized that the DPS would be able to give a more
integrated view of the disease status than the single-modality
phenotypes separately. To test this hypothesis, we looked at
the association between the three phenotypes used in our
GWAS and a set of Alzheimer’s disease genetic risk score
(GRS). A GRS represents a ‘genetic summary’ of an individ-
ual’s disease risk, combining the weighted contribution of risk
alleles across the whole genome into a single metric.
The GRS computation requires two data sources: (i) individual
level SNP data; and (ii) the SNPs effect sizes, which were ob-
tained from the largest Alzheimer’s disease GWAS study con-
ducted so far by the International Genomics of Alzheimer’s
Project (IGAP; Lambert et al., 2013). Speciﬁcally, we used the
published results on 7055881 SNPs of the discovery phase com-
prising 54162 subjects (17008 Alzheimer’s disease cases and
37154 control subjects). To avoid over-ﬁtting we only analysed
ADNI participants who did not contribute to the IGAP study.
Further, we restricted the sample to subjects with 480% prob-
ability of being of Caucasian ancestry according to SNPweights
(as detailed in the ‘Autosome imputation and quality control’
section), resulting in n = 990 study subjects. Brieﬂy, we used
15 P-value thresholds in the range 0.95–105. SNPs in the ex-
tended APOE locus (44400–46500kb on chromosome 19;
human genome release hg19) were excluded from the GRS con-
struction to enable investigations of genome-wide risk independ-
ent from APOE. For each of the P-value thresholds we selected
the ﬁnal set of SNPs for the score by using linkage disequilibrium
(LD) clumping implemented in PLINK resulting in only the most
signiﬁcant SNP above the P-value threshold within an LD
block to be selected for the score [PLINK parameters: –clump-
r2 0.2 –clump-kb 1000 as used in Escott-Price et al. (2015)].
Next, we computed the GRS for all 15 thresholds and all 990
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independent ADNI subjects. To compute the GRS, for each SNP
the number of effect alleles (i.e. 0, 1 or 2) is multiplied by the
effect size obtained from the IGAP results. The GRS is then
simply the sum of all those products and was previously used
to investigate longitudinal changes in PET biomarkers (Altmann
et al., 2016). Here, we tested the GRS for association with the
latest diagnosis available in ADNI (healthy control/MCI/
Alzheimer’s disease), and with the three quantitative phenotypes
described above, controlling for age, sex, number of APOE4
alleles, years of education, and two principal components of
population structure (Supplementary Fig. 1).
Genome-wide association analysis
Genome-wide association tests were conducted with PLINK on
the imputed SNP data (5 137 219 markers). We tested three
quantitative phenotypes (via the –linear command): bilateral
hippocampal volume at ﬁrst PET scan (926 subjects), ﬂorbeta-
pir SUVR at ﬁrst PET scan (936 subjects) and DPS (944 sub-
jects). Sample sizes differences resulted from exclusion of
poorly registered scans. The larger sample size for DPS was
due to the model’s ability to deal with missing data: if a
baseline value of hippocampus or amyloid was excluded
from the cross-sectional GWAS, GRACE was still able to
work with the remaining time points and return a DPS
(see ‘Results’ section). Table 1 reports demographics and
clinical outcomes for the DPS GWAS sample.
SNP-trait associations were tested under an additive model.
Sex, age at ﬁrst PET scan, years of education, two principal
components of population structure, and number of APOE "4
alleles were included as covariates. Since we regard DPS as a
longitudinal measure, associations were tested controlling
also for baseline levels of hippocampal volume and cortical
amyloid. Variants passing the threshold for genome-wide sig-
niﬁcance were tested for a bias introduced by the additional
covariates using the method by Aschard et al. (2015).
X chromosome variants were tested for sex-stratiﬁed associ-
ation using XWAS (Gao et al., 2015): for each SNP, linear
models were built separately for males and females, and the
resulting Z-statistics combined via Stouffer’s method.
Genome-wide signiﬁcance was deﬁned at a P-value of
5  108 or lower. Manhattan, quantile-quantile and bees-
warm plots were generated in R (R Development Core Team,
2005), and regional association plots with LocusZoom (Pruim
et al., 2011). Variants passing the genome-wide suggestive
threshold (P = 105) were annotated using the Ensembl
Variant Effect Predictor (McLaren et al., 2016). Genome-wide
signiﬁcant variants were tested for effects on gene expression
levels in 10 brain tissues by accessing data from the UKBEC
(www.braineac.org, Ramasamy et al., 2014) and followed up
in the GTEx database (Aguet et al., 2017) (date accessed:
9 May 2017) with a targeted query for a speciﬁc triplet
SNP-gene-tissue and correcting for the number of tests using
the Bonferroni method.
SNPs effect on risk of conversion
Following up on our GWAS results, we hypothesized that
variants related to disease progression through signiﬁcant
association with DPS might exert an inﬂuence on clinical con-
version from healthy control to MCI or Alzheimer’s disease.
To test this hypothesis, we ran a Competing Risks regression
analysis using the model developed by Fine and Gray (1999)
to evaluate the risk of conversion to MCI or Alzheimer’s
disease of top SNPs, while accounting for death as a compet-
ing risk. This analysis compared carriers of the minor allele
(heterozygotes and homozygotes) to non-carriers, and was car-
ried out using the cmprsk package in R (Scrucca et al., 2010).
Competing risks analysis is a type of time-to-event analysis
that aims to accurately estimate the marginal probability of
an event in the presence of competing events such as death.
This approach is relevant in this study because participants
are elderly and death may occur before the event of interest
(i.e. conversion to MCI or Alzheimer’s disease) is observed,
which can produce bias in risk estimates. This analysis used
data from three NACC Alzheimer’s disease centres, collected
between 2005 and 2015. We included all participants from the
NACC dataset who were healthy at baseline, had genotyping
data available, and had at least 1 year of follow-up, to assess
the effect of top SNPs on risk of conversion. Age at entry,
APOE "4 status, sex, years of education, ﬁrst two principal
components (Supplementary Fig. 1), and Alzheimer’s disease
centre were included as covariates in the analysis (n = 911,
Table 2). P-values were corrected for multiple comparisons
using the Bonferroni procedure.
Results
SNP imputation and quality control
After imputation and quality control, the available genetic
data comprised 5 082878 autosomal and 54 340 X-
chromosome SNP markers and 1674 subjects, with a
total genotyping rate of 0.99. No subjects were missing
more than 10% of the genotypes. After ancestry adjustment
and removal of related individuals (144 individuals that
appeared to be related), the ﬁnal sample comprised 1499
unrelated Central European individuals. For the X chromo-
some, there were 1329 Central European unrelated subjects
because of additional X-speciﬁc pre-imputation quality con-
trol (Gao et al., 2015).
Quantitative traits
Registration failure between PET scans and time-matched
T1-weighted MRI scans was detected in 16 subjects.
Hippocampal volumes concurrent with a correctly regis-
tered baseline PET scan were available for 1065 subjects.
Of these, genetic data were available for 926 unrelated
Central European subjects. SUVR values were available
for 1089 subjects. For 11 of them, registration failure
occurred on the baseline PET scan; consequently, these
SUVR values were excluded. Of the remaining 1078 indi-
viduals, genetic data were available for 936 unrelated
Central European subjects.
Disease progression scores
Figure 2A shows the long-term dynamic trajectories ﬁtted
by GRACE to the ﬂorbetapir SUVR and hippocampal
volume data. DPS values were available for 1085 subjects;
2172 | BRAIN 2018: 141; 2167–2180 M. A. Scelsi et al.
genetic data were available for 944 unrelated Central
European subjects. Mean DPS was signiﬁcantly higher in
early MCI (P = 9  104) and late MCI (P = 4.36  1013)
than in healthy control, higher in late MCI than in early MCI
(P = 4.81  1013), and higher in Alzheimer’s disease than in
healthy control (P = 4.36  1013), subjective memory com-
plaints (P = 4.36  1013), early MCI (P = 4.36  1013)
and late MCI (P = 5.23  1013, Fig. 2B). Supplementary
Fig. 3 shows the DPS distributions for the different MCI
progression status. DPS showed better effect sizes (Cohen’s
d) in separating healthy control and Alzheimer’s disease
subjects as well as MCI and Alzheimer’s disease subjects
compared to both cross-sectional hippocampal volume and
cortical amyloid alone, and their longitudinal rate of change
(Supplementary Fig. 4 and Supplementary Table 2). There
was no difference across cross-sectional biomarkers in separ-
ating healthy controls and MCI, whereas DPS outperforms
rates of change in hippocampal volume and amyloid for this
task.
Effect of APOE4 status on quantita-
tive traits
APOE4 allele count was strongly correlated with all
three phenotypes. Without any covariate adjustments,
hippocampal volume exhibited a negative correlation
(Pearson’s r = 0.12, P = 1.8  104), while cortical amyl-
oid (r = 0.44, P5 2.2  1016) and DPS (r = 0.35,
P5 2.2  1016) were positively correlated. When adjusting
for age and sex, the correlations with APOE4 allele count
were strengthened for hippocampal volume (Pearson’s
r = 0.21, P5 2.2  1016), cortical amyloid (r = 0.47,
P5 2.2  1016) and DPS (r = 0.41, P52.2  1016).
Relation between phenotypes and
Alzheimer’s disease polygenic risk
score
As a preliminary point, we veriﬁed that the GRS that incor-
porated many weakly associated variants were signiﬁcantly
associated with Alzheimer’s disease diagnosis, when
discriminating healthy controls from MCI (minimal
P = 1.44  103) and healthy controls from Alzheimer’s
disease (minimal P = 2  104; Fig. 4A). This behaviour is
consistent with results reported in the literature (Escott-
















































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2 Demographics for the NACC participants
included in the competing risks regression analysis
Total (n = 911)
APOE "4, carriers/non-carriers 249/662
Age, years (SD) 74.9 (8.75)
Education, years (SD) 15.9 (2.70)
Sex, female/male 549/362
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strongest association with GRS at low P-value cut-offs
(P = 105, 104, 103), i.e. scores that include established
Alzheimer’s disease risk variants (Fig. 4B). Only the asso-
ciation between DPS and GRS at P-value cut-off 104 was
signiﬁcant after Bonferroni correction. Furthermore, at the
same P-value cut-off, the GRS exhibits a stronger associ-
ation with DPS than the GRS at high P-value cut-offs
(e.g. 0.7) in the healthy control versus Alzheimer’s disease
setting.
Genome-wide association tests
A genome-wide signiﬁcant association was found for the
DPS on chromosome 4 at rs6850306 (MAF = 0.15,
P = 1.03  108; Fig. 3C and Supplementary Table 3).
The second most strongly associated locus was
rs114368656 on chromosome 22 (sample MAF = 0.08,
P = 1.70  106, Fig. 3C). Supplementary Figs 6 and 7
show the regional association plots. Supplementary Fig. 8
shows the DPS distributions stratiﬁed by rs6850306 and
rs114368656 genotype, after adjusting for the covariates
used in the GWAS. No signiﬁcant associations were
found for either hippocampal volume or cortical amyloid
(Fig. 3A and B). Supplementary Table 3 lists the 13, 14 and
12 suggestive independent loci for hippocampal volume,
cortical amyloid and DPS, respectively. The DPS results
include genetic loci that were neither suggestive by amyloid
burden (rs6850306: P = 0.87; rs114368656: P = 0.96)
nor by hippocampal volume (rs6850306: P = 0.21;
rs114368656: P = 0.16) alone, and that have not been re-
ported in the case-control meta-analysis by Lambert et al.
(2013) (rs6850306: P = 0.17; rs114368656 was not tested).
Association signiﬁcance with DPS remained almost unchanged
when testing imputed dosages in place of genotypes (i.e. for
rs6850306 P = 1.22  108; for rs114368656
P = 1.92  106). There was no evidence for P-value inﬂation
with 5 1.062 (Supplementary Fig. 5). Summary statistics
are publicly available at https://doi.org/10.6084/m9.ﬁgshare.
5603203.v5 (autosomes and chromosome X separately; sum-
mary statistics for males and females separately as returned by
XWAS can be found in the X chromosome ﬁles).
The SNP rs6850306 acts as expression quantitative trait
locus (cis-eQTL) for the LCORL gene in the hippocampus
(minimal P = 0.035, GTEx), and speciﬁcally for the exon
probe sets 2720253 and 2720265 of the Affymetrix
Human Exon 1.0 ST array in the same brain tissue
(minimal P = 6.9  104, UKBEC, Supplementary Fig. 9).
As expected from the correlations reported in the ‘Effect of
APOE4 status on quantitative traits’ section, for hippocampal
volume and amyloid, once the number of APOE4 alleles was
not included as covariate in the association studies, signiﬁcant
association was found for the APOE locus with both
Figure 2 Disease progression modelling results. (A) Long-term progression curves for two Alzheimer’s disease biomarkers. Every point in
the plot represents a biomarker measurement; longitudinal data from the same subject are connected by lines. The subjects’ clinical diagnosis at
the initial PET scan is colour-coded. The x-axis shows the time from study entry plus the estimated DPS, values on the y-axis are the Z-score
normalized individual biomarker measurements: florbetapir PET SUVR and intracranial-volume-normalized bilateral hippocampal volume.
(B) Disease progression scores stratified by diagnosis at baseline PET scan. The y-axis shows the DPS and the x-axis corresponds to different
diagnostic groups of increasing severity from left (Normal) to right (Alzheimer’s disease). Each box shows the DPS distribution for the
corresponding diagnostic group. Annotations represent the level of statistical significance for pairwise tests, after correction for multiple
comparisons (*** P5 0.001). EMCI = early MCI; LMCI = late MCI; SMC = subjective memory complaints.
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Figure 3 Manhattan plots for the three GWASs. Cross-sectional hippocampal volume (A), cross-sectional amyloid burden (B), disease
progression score (C), after correcting for age, sex, number of APOE "4, years of education, baseline cortical amyloid and hippocampal volume,
and two principal components of population structure. The red line is the genome-wide significance threshold at P = 5  108; the blue line is a
threshold for suggestive associations at P = 105.
Figure 4 Significance of association between Alzheimer’s disease polygenic risk score at different SNP inclusion thresholds
and binary and continuous phenotypes. (A) Diagnosis coded as three different logistic regressions [healthy control (HC) versus Alzheimer’s
disease (AD), healthy control versus MCI, MCI versus Alzheimer’s disease]. (B) The three quantitative traits used as outcomes in GWASs. The
x-axis shows the number of SNPs included in the computation of the GRS (on logarithmic scale). We selected from the results of the IGAP GWAS
SNPs that exceeded a P-value cut-off ranging from 105 (55 SNPs) to 0.95 (179 211 SNPs). The y-axis represents the strength of association
(P-value for the regression coefficient in a general linear model, logarithmic scale) between the GRS and the outcome variables. The black line is
the 0.01 significance threshold after Bonferroni correction for the effective number of independent tests performed. The effective number of
independent GRS (Meff,GRS) and phenotypes (Meff,phen) tested was computed following the simpleM method in Gao et al. (2008). (A) Significance
level adjusted for Meff,GRS only. (B) Significance level adjusted for both Meff,GRS and Meff,phen.
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hippocampal volume (rs429358 P = 1.34  1010) and cor-
tical amyloid (rs429358 P = 2.54  1050) (Supplementary
Fig. 10), in excellent agreement with previously published
results (Schuff et al., 2008; Drzezga et al., 2009). Similarly,
a strong association between the APOE locus and DPS can
be seen when both the corrections for APOE4 status and
baseline cortical amyloid are dropped (rs429358
P = 4.43  1033; Supplementary Fig. 10D). The inclusion
of correlated traits as confounders in the DPS GWAS did
not introduce any bias in the estimated effect size for
rs6850306 (Wald test statistic W = 0.14, P = 1).
SNPs effect on risk of conversion
Competing risks regression analysis in the NACC dataset was
conducted for the two top SNPs rs6850306 (GWAS
b = 0.07; P = 1.03  108) and rs114368656 (GWAS
b = 0.05; P = 1.70  106). Given the relatively low minor
allele frequency of both rs6850306 and rs114368656, the
analysis was conducted on minor allele carriers (recessive
homozygotes and heterozygotes) versus non-carriers (major
allele homozygotes). rs6850306 appears to be protective
against conversion [hazard ratio (HR) = 0.593, 95%
CI = 0.387–0.907, n = 911, PBonf = 0.032], conferring
decreased risk to homozygous and heterozygous carriers of
the minor allele A and conﬁrming the negative direction of
effect reported in the GWAS (Fig. 5A and Supplementary
Table 3). However, results suggest that rs114368656 does
not modulate conversion risk between carriers and non-car-
riers of the minor allele T (HR = 1.08, 95% CI = 0.737–1.57,
n = 480, PBonf = 1; Fig. 5B).
Discussion
We assessed the potential of a compound phenotype com-
prising cortical amyloid and hippocampal volume to
discriminate disease stages in Alzheimer’s disease. The
DPS exploits the different temporal properties of the indi-
vidual biomarkers: brain amyloid accumulation begins
during the prodromal phase where no cognitive decline is
manifest; hippocampal atrophy tends to be detectable later
during the disease course closer to clinical symptoms (Jack
et al., 2010). The resulting DPS increased with increasing
severity of the clinical diagnosis (Fig. 2B), was related to
longitudinal disease progression (Supplementary Fig. 3) and
was superior to the individual biomarkers in separating
Alzheimer’s disease subjects from healthy controls or MCI
subjects (Supplementary Fig. 4). In addition, the DPS
showed a stronger association with genome-wide polygenic
Alzheimer’s disease risk than the individual biomarkers
(Fig. 4B).
Having shown the advantage of the DPS over individual
biomarkers in tracking disease progression, the DPS was
used as a quantitative phenotype in a GWAS. Genome-
wide signiﬁcant rs6850306 and its haplotype fall in the
LCORL gene on chromosome 4p15.31. For this variant
we identiﬁed a tissue-speciﬁc effect on LCORL expression
levels in the hippocampus, with expression levels increasing
with each copy of the minor allele; this cis-eQTL behaviour
was consistently found in two independent gene expression
databases.
The protein encoded by LCORL is a direct interaction
partner of CTBP1 (Szklarczyk et al., 2015), which mediates
activity-dependent synapse-to-nucleus communication
(Ivanova et al., 2015). Furthermore, the CTBP1/BARS com-
plex co-localizes with amyloid precursor protein (APP) in
macropinosomes at the cell surface (Tang et al., 2015).
Previous GWAS have linked LCORL to human height
(Wood et al., 2014). Interestingly, human height exhibits
a negative genetic correlation with Alzheimer’s disease
(Bulik-Sullivan et al., 2015).
Among the suggestive variants, a haplotype on chromo-
some 22 falls in the SYN3/TIMP3 gene. Of note, SYN3/
Figure 5 Cumulative distribution functions (complementary survival functions) for risk of conversion to MCI or Alzheimer’s
disease against months from baseline for NACC study participants. (A) Results stratified by rs6850306 minor allele carriers versus
non-carriers (A/A and A/G versus G/G); (B) stratified by rs114365686 minor allele carriers versus non-carriers (T/T and T/C versus C/C).
AD = Alzheimer’s disease.
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TIMP3 was also identiﬁed as susceptibility locus for age-
related macular degeneration (Chen et al., 2010; Fritsche
et al., 2016), a late-onset neurodegenerative disease of the
retina involving amyloid-b pathology (Ratnayaka et al.,
2015). It has also been suggested that upregulation of
TIMP3 may occur at an early disease stage, playing an
important role in the development of neuroﬁbrillary tangles
(Dunckley et al., 2006). A number of interesting association
signals to neurodegenerative diseases have been reported in
this region on chromosome 22 (Lachman et al., 2006;
Otaegui et al., 2009; Zaltieri et al., 2015). However,
some caution is required when interpreting these associ-
ation signals due to scarce coverage on some genotyping
platforms and lack of information on LD structure in the
1000 Genomes reference panel and all resources based on
it. In fact, the ADNI whole-genome sequencing data called
no variants in the 5 kb region surrounding rs114368656.
We believe this is due to the general architecture of the
locus, that is characterized by several insertions/deletions
and copy-number variations of different lengths.
We demonstrated the ﬁrst successful application of a
multimodal DPS as quantitative phenotype in a GWAS.
There remain, however, some limitations. First, the DPS
relies heavily on the choice of considered biomarkers. In
this study, amyloid burden and hippocampal volume were
used owing to their speciﬁcity to Alzheimer’s disease path-
ology. However, larger or different sets of biomarkers may
provide more granular estimates of disease progression,
which may translate into increased statistical power for
reaching genome-wide signiﬁcance. Second, the multimodal
nature of the DPS complicates validation in independent
cohorts. In fact, for this work we could not secure a sufﬁ-
ciently sized cohort with genotyping, longitudinal amyloid
and structural imaging data to validate our ﬁndings.
Although lacking a formal replication cohort, a supporting
evidence for our genome-wide signiﬁcant association in
chromosome 4 comes from the conversion risk analysis
performed on an independent dataset (NACC), conﬁrming
the protective role of rs6850306 revealed through GWAS
and linking rs6850306 genotype, lower DPS values and
decreased risk for conversion. Additionally, there is
supporting evidence for the two top associated loci in the
literature; linking one locus to age-related macular degen-
eration, which shares many genetic similarities with
Alzheimer’s disease including APOE as a risk locus.
Third, despite their inherent appeal for genetic studies, ima-
ging-derived phenotypes may also be a source of undesired
variation. For instance, our analysis of cross-sectional
amyloid burden (Fig. 3B) did not show a signiﬁcant asso-
ciation at rs509208, which was identiﬁed in an earlier
study using a subset of these data (Ramanan et al.,
2014). The discrepancy may originate from slightly differ-
ent sample sizes and the use of a different pipeline to
compute brain amyloid burden, highlighting the need for
robust imaging biomarkers such as the DPS presented here.
Lastly, despite the several lines of evidence here presented
(statistical association, cis-eQTL, modulation of conversion
risk), these are not sufﬁcient to claim the identiﬁcation of a
protective gene for Alzheimer’s disease: this can only be
achieved through ﬁne-mapping of the genomic region of
interest and follow-up with functional studies and animal
models. Without conﬁrmation from these studies, any other
gene in the locus can potentially be the causal gene.
In summary, we performed the ﬁrst successful genetic
study of a progression score for Alzheimer’s disease derived
from multiple imaging modalities. We believe that this in-
tegrative approach has great potential for identifying
common genetic variation related to the multiple, inter-
linked pathogenic pathways involved in Alzheimer’s disease
and other complex diseases.
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